Curated news and analysis on clinical trials, drug approvals, and medical research.
Genentech's Phase III MAJESTY study showed Gazyva achieved statistically significant complete remission rates versus tacrolimus in primary membranous nephropathy, a chronic autoimmune kidney disease affecting over 96,000 people in the U.S.
Scientists at UC San Diego have identified N4BP2 as the enzyme responsible for chromothripsis, a chaotic chromosome-shattering event seen in about one in four cancers that enables rapid tumor evolution and treatment resistance.
Natco Pharma received CDSCO approval to manufacture and launch generic semaglutide injection in India next month for type 2 diabetes treatment, sending shares up over 11% on Monday.
CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.
Blood-based biomarkers including brain-derived tau and amyloid-beta are enabling earlier Alzheimer's disease diagnosis through non-invasive testing, though confirmatory imaging remains necessary before treatment initiation.
Shanghai Henlius Biotech received U.S. FDA approval to begin phase 1 trials of HLX15-SC, a subcutaneous biosimilar of daratumumab, for multiple myeloma treatment with significant commercial potential.
Novartis has agreed to acquire Avidity Biosciences in the first half of 2026, obtaining its RNA therapeutics platform and neuromuscular disease pipeline. Avidity's cardiovascular RNA programs will be separated into a new independent company called Atrium.
The FDA reversed its initial refusal and will now review Moderna's mRNA-based flu vaccine application, seeking full approval for adults 50-64 and accelerated approval for those 65 and older, with a decision targeted for August 5, 2026.
Health and Human Services Secretary Robert F. Kennedy Jr. announced the FDA will act on a petition to revoke GRAS status for dozens of processed sweeteners and starches, including corn syrup, unless companies prove they are safe.
WHOOP has partnered with Unilabs to launch its Advanced Labs programme in the UAE, offering members access to a 65-biomarker blood testing panel at Dhs733, with results integrated into the WHOOP app alongside wearable health data.
HHS Secretary Robert F. Kennedy Jr. announced the FDA will consider a petition to revoke GRAS status for dozens of processed sweeteners and starches, though he stopped short of promising new regulations on ultraprocessed foods.
Australia's Medical Research Future Fund announces two 2026 grant opportunities totaling $98 million for research infrastructure and international clinical trial collaborations.
CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.
Eli Lilly committed $1 billion to build an AI-powered supercomputer with Nvidia for drug discovery, launching its TuneLab platform in September and establishing a co-innovation lab by January.
A phase IIa clinical trial found that a single intravenous dose of dimethyltryptamine (DMT) with psychological support rapidly reduced depressive symptoms in 34 adults with major depressive disorder, with improvements sustained for up to three months.
Researchers at Monash University have identified DNA sequence variations in mothers that modify the risk of birth defects from valproic acid, an anti-seizure medication, paving the way for a genetic test to identify who can safely take the drug during pregnancy.
The provided articles contain local crime reports and general news aggregation content with no medical or pharmaceutical information to synthesize.
CSL Seqirus announced that neffy adrenaline nasal spray has been approved in Australia for emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over, marking the first new adrenaline administration method approved in over 30 years.
The Indian Health Service announced it will phase out mercury-containing dental amalgams by 2027, citing environmental and health concerns. The move affects roughly 2.8 million patients and aligns with global efforts to reduce mercury exposure.
Researchers identified shared white matter alterations in the corpus callosum as a common biomarker across schizophrenia and bipolar disorder, supporting the concept of a psychosis spectrum rather than distinct disorders.
